Focused On-demand Libraries - Receptor.AI Collaboration


Explore the Potential with AI-Driven Innovation

This comprehensive focused library is produced on demand with state-of-the-art virtual screening and parameter assessment technology driven by Receptor.AI drug discovery platform. This approach outperforms traditional methods and provides higher-quality compounds with superior activity, selectivity and safety.


From a virtual chemical space containing more than 60 billion molecules, we precisely choose certain compounds. Reaxense aids in their synthesis and provision.


Contained in the library are leading modulators, each labelled with 38 ADME-Tox and 32 physicochemical and drug-likeness qualities. In addition, each compound is illustrated with its optimal docking poses, affinity scores, and activity scores, giving a complete picture.


We employ our advanced, specialised process to create targeted libraries.


 

Fig. 1. The screening workflow of Receptor.AI

Our methodology employs molecular simulations to explore a wide array of proteins, capturing their dynamic states both individually and within complexes. Through ensemble virtual screening, we address conformational mobility, uncovering binding sites within functional regions and remote allosteric locations. This thorough exploration ensures no potential mechanism of action is overlooked, aiming to discover novel therapeutic targets and lead compounds across an extensive spectrum of biological functions.


Several key aspects differentiate our library:


  • Receptor.AI compiles an all-encompassing dataset on the target protein, including historical experiments, literature data, known ligands, and structural insights, maximising the chances of prioritising the most pertinent compounds.

  • The platform employs state-of-the-art molecular simulations to identify potential binding sites, ensuring the focused library is primed for discovering allosteric inhibitors and binders of concealed pockets.

  • Over 50 customisable AI models, thoroughly evaluated in various drug discovery endeavours and research projects, make Receptor.AI both efficient and accurate. This technology is integral to the development of our focused libraries.

  • In addition to generating focused libraries, Receptor.AI offers a full range of services and solutions for every step of preclinical drug discovery, with a pricing model based on success, thereby reducing risk and promoting joint project success.


PARTNER
Receptor.AI
 
UPACC
Q9Y3B1

UPID:
PLD3B_HUMAN

ALTERNATIVE NAMES:
Protein slowmo homolog 2

ALTERNATIVE UPACC:
Q9Y3B1; E1P5I8; Q5JX17; Q9NUL0

BACKGROUND:
The PRELI domain containing protein 3B, with alternative names such as Protein slowmo homolog 2, is pivotal in cellular biology. This protein's architecture, characterized by the PRELI domain, indicates a significant role in intracellular transport or mitochondrial function, essential for cell survival and communication.

THERAPEUTIC SIGNIFICANCE:
Exploring the functions of PRELI domain containing protein 3B holds the promise of unveiling new therapeutic avenues. As it is central to critical cellular mechanisms, targeting this protein could lead to innovative treatments for diseases caused by cellular malfunctions.

Looking for more information on this library or underlying technology? Fill out the form below and we will be in touch with all the details you need.